The peroxisome proliferator-activated receptor-gamma agonist, Rosiglitazone, improves aortic wall stiffness in type 2 diabetic patients

Song, Mi Jin; Kim, Nam Ho; Choi, Joon Ho; Park, Eun Mi; Kim, Yeon Kyung; Yun, Kyeong Ho; Yoo, Nam Jin; Lee, Eun Mi; Oh, Seok Kyu; Jeong, Jin Won; Park, Ock Kyu

Abstract

BACKGROUND: Diabetes is a major risk factor for the development of coronary artery disease. Atherosclerosis is thought to arise as a result of a chronic inflammatory process within the arterial wall. Insulin resistance is central to the pathogenesis of type 2 diabetes and may contribute to atherosclerosis, either directly or through associated risk factors. Rosiglitazone, a peroxisome proliferator-activated receptor gamma agonist, is used in the treatment of type 2 diabetes mellitus, and previous findings suggest that it may have anti-inflammatory effects on atherosclerosis. This study was performed to evaluate whether rosiglitazone can improve arterial stiffness in type 2 diabetic patients.
METHODS
This study consisted of 40 patients with type 2 diabetes. These subjects were classified into two groups either medicated with glimepiride (GLIME group, 61.5+/-8.2 years, M:F = 9:11) or with glimepiride and rosiglitazone (ROSI group, 65.6+/-9.5 years, M:F = 4:16). For each group, plasma a hsCRP, lipid profile, HOMAIR and HbA1c were measured before and after 12 months of medical treatment. At the same time, pulse wave velocity (PWV) using an automatic device (PP 1000, Hanbyul, Jeonju, Korea) was measured.
RESULTS
The plasma hsCRP level was significantly decreased in the ROSI group as compared with the GLIME group (4.22+/-4.65 vs. 1.07+/-0.80 mg/L, p=0.025). The carotid-femoral PWV of the ROSI group improved significantly as compared with the GLIME group (8.29+/-1.25 vs. 7.26+/-1.49 m/sec, p=0.024). The changes of PWV were correlated with the changes of hsCRP (r=0.412, p=0.033).
CONCLUSIONS
These findings suggest that rosiglitazone can improve the arterial stiffness in type 2 diabetic patients.